|
Deal Making and Structuring Early-Stage Technology and Life Science Deals
hosted by the New York/New Jersey Chapter
Wednesday, June 12, 2024 5:30pm - 7:30pm
at
Stevens Institute
Lawrence T. Babbio, Jr. Center for Business and Technology
525 River Road
Hoboken, NJ 07030 Mass Transit: NJ Transit or PATH Train to Hoboken. NY Waterway Ferry to Hoboken.
Once in Hoboken, take a 5 min Uber/cab or walk uptown to 6th Street and turn right (east) for the campus (15 min). 
Click here for a campus map Thank you to our event sponsor: 
Program:
Panel discussion on the challenges and opportunities associated with technology transfer and licensing from universities to corporates and between emerging companies and more established companies.
Topics covered by panelists following a networking reception will include: - What’s critical to get right in early-stage Licensing / technology transfer deals or acquisitions.
- What should University, corporate and early stage licensing professional know when doing the deal and various structures to ensure success and bridge valuation gaps.
- Challenges for the licensee or acquirer post the transaction as they pursue commercialization.
- What Late-Stage Companies that inherit these early-stage deals should be aware of
- How High tech/device early stage deals differ from Life science deals.
- Panelists will draw from real-life experience and provide examples based on executed deals such as
- University licensing of a health tech product
- In and out licensing of pharmaceutical drugs
- In and out licensing of drug delivery technology
In addition, a representative from the New Jersey Economic Development Authority will also provide an overview of the programs geared towards innovative life science and high-tech companies.
Target Audience: University tech transfer professionals, early-stage Life science and technology companies, late-stage companies that recently acquired or in licensed IP originated at early-stage companies. Speakers: 
| Lori Lonczak, RPh, MBA Lori is a Board Member of JET Worldwide Inc or CatchU – a digital health startup company spun out of Albert Einstein College of Medicine.
Lori is also President of Lori Lonczak Consulting, LLC (DBA Stratify®); a consulting business focused on consumer and pharmaceutical brands, and portfolio strategy, for companies ranging from start-up to Fortune 50. In 2017, Lori was named a Woman of the Year by Enterprising Women Magazine, when Stratify achieved sales among the top 3% of women-owned businesses in the US. Lori is also a coach at the WCBA and ELab business accelerators in New York.
Lori has over 30 years of pharmaceutical business leadership experience with Vice President level roles in three key commercial areas: sales, marketing (line and global strategic) and corporate strategy. Throughout her career, Lori is known for developing innovative business insights and strategies that drive brand and company results.
Previously, Lori was a Board member at Common Sense, Ltd., which had a successful exit in 2017; and she served for 14 years on the Rutgers University School of Pharmacy Board. | 
| David Jin, CFO and Head of Corporate Development, Fortress Biotech David has served as the Chief Financial Officer of Fortress Biotech since August 2022 and as Head of Corporate Development since May 2020. He also serves as Interim Chief Financial Officer and Chief Operating Officer of Avenue Therapeutics, Inc. (a Fortress partner company). Previously, he was on the investment team in the Private Equity & Real Assets group at Barings, Director of Corporate Development at Sorrento Therapeutics, Vice President of Healthcare Investment Banking at FBR & Co., and was in the management consulting group at IMS Health (now IQVIA). He holds a B.S. in Industrial Engineering & Management Sciences with a double-major in Mathematical Methods in the Social Sciences from Northwestern University. | 
| Tushar Nuwal, Chief Operating Officer and Chief Business Officer, Ligandal Tushar Nuwal is the Chief Operating Officer and Chief Business Officer at Ligandal, an early-stage genetic medicine biotechnology company.
Tushar is a global pharmaceutical veteran.
His leadership spans across R&D, manufacturing, product & launch management, operations, business & corporate development, licensing, portfolio, and commercial strategy. His most recent role was Vice President at Polypid Inc., where he led BD&L. Prior to that, he was Executive Director of BD&L at Sandoz, a $10 billion division of Novartis.
Tushar’s career is marked by impressive achievements. He successfully led and closed over $2 billion in transactions and launched products generating over $1 billion in annual revenue. His experience includes roles at Pfizer Pharmaceuticals, Endo Pharmaceuticals, Purdue Pharma, and Fresenius Kabi.
Tushar holds a B.S. in Chemical Engineering and Economics from Rensselaer Polytechnic Institute, an M.S. in Transactional & IP Law from Northwestern University, a post-graduate diploma in Finance from New York University, and is currently enrolled in a medical sciences certificate program at Harvard University.
| 
| Lori Waldron, Co-Chair, Sills Cummis & Gross Life Sciences Practice Group Lori is Co-Chair of the Sills Cummis & Gross Life Sciences Practice Group. Her practice focuses on representation of public and private companies in sophisticated business transactions, with a focus on representation of clients in the life sciences and pharmaceuticals sectors. Ms. Waldron has extensive experience drafting and negotiating strategic alliance agreements, joint venture agreements, intellectual property license agreements, co-promotion agreements and supply agreements. She also has substantial experience representing early and late stage companies with respect to venture capital financings, mergers and acquisitions, and general corporate needs. Prior to joining Sills Cummis & Gross, Ms. Waldron was Assistant General Counsel at a national consulting firm with a large presence in the pharmaceuticals industry. Ms. Waldron is able to combine her business background and her M.B.A. with her legal knowledge to provide clients with full service representation. |
Cost includes light refreshments and appetizers/snacks 
Email Consent
By registering for this event, you permit LES to use your email address to communicate with you regarding LES events and their other services. You will have the ability to unsubscribe from these communications going forward.
|
Print Page
